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Abstract.  Cultured TA1  adipocytes treated with tumor 
necrosis factor alpha (TNF) lose intracytoplasmic lipid 
and,  over a period of days, come to resemble their 
predifferentiated progenitors  (preadipocytes). To exam- 
ine the extent to which this phenotypic reversion 
represents a  return to a  less differentiated cell, we ex- 
amined three major characteristics  that distinguish 
preadipocytes from adipo~tes:  (a) pattern of gene ex- 
pression;  (b) hormonal  requirement for accelerated 
adipogenesis; and (c) pattern of protein synthesis. We 
found that within hours of TNF addition to adipocytes, 
mRNAs for genes whose expression is augmented dur- 
ing adipogenesis decreased to predifferentiated levels; 
in addition,  like preadipocytes, TNF-treated adipocytes 
required exposure to hormones to accelerate adipogen- 
esis.  Further,  the pattern of protein synthesis seen on 
polyacrylamide gels reverted to that seen before 
differentiation.  Transforming growth factor-beta (TGF- 
/3) also caused a  rapid decrease in expression of adi- 
pose genes when added to fully differentiated cells, an 
effect that was achieved by treatment with either TGF- 
~  or TGF-/32. These effects were seen in the absence 
of a demonstrable proliferative response to either TNF 
or TGF-/L  Thus characteristics  that define the "termi- 
nally" differentiated state in adipocytes are subject to 
modulation by environmental  influences. 
T  H  E acquisition of a specialized phenotype, which char- 
acterizes the latter stages of differentiation of cells and 
tissues, is associated with the coordinate expression of 
new genes and the concomitant loss of expression of genes 
specific to the less differentiated cell. Although it is generally 
believed that this process is unidirectional,  the differentiated 
state of a cell can be altered  under experimental  situations. 
"Reprogramming"  experiments,  which can be accomplished, 
for example,  by fusing cells of different lineages  in culture 
(6), presumably reflect the presence of diffusible factors that 
regulate the state of differentiation.  In recent experiments  in 
nonfusing  myogenic cell lines,  fibroblast growth factor has 
been shown to reverse muscle-specific gene expression inde- 
pendent of cell proliferation  (14). In the experiments  de- 
scribed below we consider the possibility that some differen- 
tiative events in adipocytes may be, at least in part, reversible 
and regulated by two products of activated macrophages:  tu- 
mor necrosis factor alpha  (TNF) ~ and transforming  growth 
factor beta (TGF-fl). 
TNF, initially described as an agent with necrotic effect on 
tumors (8), has recently been shown to have a wide variety 
of effects on normal cells as well.  For example,  TNF has 
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been shown  to affect endothelial  cells,  modifying the en- 
dothelial  surface to accelerate the transport of phagocytes 
across the capillary  wall (18, 28). In addition,  TNF stimu- 
lates  endothelial  cells to produce granulocyte/macrophage 
colony stimulating  factor (7) and augments  cellular expres- 
sion of HLA-A,B antigens (15). TNF inhibits myogenesis in 
human muscle cells (26) and augments expression of ferritin 
heavy chain in both human muscle cells and adipocytes (44). 
TNF also mediates the fever and vascular instability (shock) 
which accompany endotoxemia (45), and may play an impor- 
tant role in the cachexia of chronic infections and cancer (3, 
30,  43).  TGF-/~ also  exhibits  potent,  but generally  quite 
different,  effects on a wide variety  of cell types. It inhibits 
the proliferation  of epithelial  cell lines while stimulating  the 
proliferation  of some mesenchymal  cells; some of these ef- 
fects may be achieved through elevated expression of compo- 
nents of the extracellular  matrix (25). In addition, TGF-/3 has 
profound effects on the expression of specific phenotypes in 
cells that differentiate:  TGF-~/promotes  chondrogenesis  and 
epithelial  cell differentiation  while blocking adipogenesis, 
myogenesis,  and hematopoiesis in vitro (42), 
Among  the best characterized  tissue culture models of 
differentiation  are sublines of fibroblasts  that,  upon growth 
arrest and appropriate hormonal manipulation,  exhibit  the 
characteristics  of adipocytes (10, 11, 19, 23, 33). We have re- 
cently observed that  cachectin,  a  monokine produced by 
endotoxin-stimulated  macrophages,  specifically  inhibits the 
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expression is characteristic of adipocytes (43).  By sequence 
homology (4) and function (27, 43) TNF and cachectin have 
proven to be the same molecule. In light of the close morpho- 
logical similarity observed in our earlier experiments be- 
tween preadipocytes and cachectin-treated adipocytes, we 
were led to examine whether recombinant TNF might be 
capable of modulating the differentiated state in these cells. 
Further, since TGF-B has recently been shown to be a prod- 
uct of activated macrophages (2) and has been reported to in- 
hibit adipocyte differentiation (20, 41), we examined whether 
TGF-/5 might also evoke a pattern of gene expression charac- 
teristic of the predifferentiated adipocyte. 
Materials and Methods 
Cell Culture and Hormonal Treatment 
TAI cells (10), an adipogenic cell line derived from 5-azacytidine treatment 
of  10T1/2 C18  cells (33),  were grown in Eagle's basal  medium (Gibco 
Laboratories, Grand Island, NY), supplemented with 10%  FBS (Gemini 
Bio-products, Inc., Calabasas, CA) heat inactivated for 30 min at 56°C. In 
certain experiments FBS was replaced with defined supplemented calf se- 
rum (HyClone Laboratories, Logan, UT). Cells were maintained at 37°C 
in a humidified incubator in 5% CO2. Cultures were fed every 3 d. The day 
at which cells reach confluence is referred to as day 0. Differentiation was 
accelerated either by the addition of media supplemented with  10  -6 M 
dexamethasone plus 1.25  ×  10  -4 M indomethacin from day 0 to day 3 or 
by the addition of indomethacin (at 0.3-1.25  x  10  -4 M) alone. After cells 
had been induced to differentiate they were maintained in growth medium 
without hormones. Human recombinant tumor necrosis factor (specific ac- 
tivity  =  107 U/mg rTNF) (Cetus Corp., Emeryville, CA) was added at a 
final concentration of I U/ml. TGF-~ (unfractionated), TGF-~I, and TGF- 
/~2, purified from porcine platelets, were purchased from R & D Systems, 
Inc. (Minneapolis, MN). 
RNA Isolation 
Total RNA was prepared from adipocyte cultures as described by Chirgwin 
et al. (13). Cells were washed with PBS and lysed by the addition of a solu- 
tion of 4 M guanidinium thiocyanate, 25 mM sodium citrate, 0.2% N-lauryl 
sarcosine, and 0.2 mM B-mercaptoethanol applied directly to the culture 
dishes. The cell lysate was layered on 5.7 M cesium chloride and centrifuged 
at 80,000 g for 19-24 h. The RNA pellet was resuspended in 10 mM Tris 
pH 7.4  +  1 mM EDTA (TE), extracted with a 4:1  solution of chloroform 
and N-butanol, and precipitated in 2.5 vol 95% ethanol. 
RNA Analysis 
For Northern analysis, 10 tzg of total RNA was brought to a final concentra- 
tion of 2.2 M formaldehyde, 30%  formamide, 10 mM sodium phosphate, 
pH 7.0, and heated for 15 min at 56°C.  Samples were subjected to elec- 
trophoresis in a .1.0% agarose formaldehyde gel and transferred to nitrocel- 
lulose either directly or after alkali  treatment. For dot blots, serial twofold 
dilutions of 3 #g of total RNA were applied to nitrocellulose in a dot blot 
apparatus (Bethesda Research Laboratories, Gaithersburg, MD). Before ap- 
plication to nitrocellulose, RNA samples were incubated at 56°C for 15 
min. 
Transcription Assays 
Assays were performed using the method described by Vannice et al. (46), 
as modified by Knight et al. (23) and Torti et al. (43) for adipose cells. Cul- 
tured cells were chilled to 4°C, media aspirated, and cells washed with PBS. 
Hypotonic buffer (20 mM Tris-HCl, pH 8.0, 4 mM MgCI2, 6 mM CaCI2, 
0.5 mM fliT; 1.5 ml) was added to plates. After 5 min, 1 ml oflysis buffer 
(0.6 M sucrose, 0.2% [wt/voll NP-40, 0.5 mM DTT) was added, and cells 
were scraped from the tissue-culture dishes. After homogenization, nuclei 
were pelleted at 500 g, washed once in resuspension buffer (0.25 M sucrose, 
10 mM Tris-HCl, pH 8.0, 10 mM MgCI2,  1 mM DTT)  repeileted, then 
resuspended in 50 mM Hepes, pH 8.0, 90 mM NI-I4CI, 5 mM MgCI2, 0.5 
mM MnCI2,  2 mM DTT, 0.1 mM EDTA, 0.4 mM each of ATP, CTP, and 
GTP,  10% glycerol, and 10 #g/ml BSA. Nuclei were incubated with alpha 
32p-UTP (3,200 Ci/mmol; ICN Radiochemicals, Irvine, CA) at a concen- 
tration of 2 mCi/ml for 40 min at 25°C with gentle shaking. 
RNA was harvested from nuclei as described by Smith et al.  (40)  and 
modified by Knight et al. (23), and hybridized to linearized cDNAs that had 
been applied to nitrocellulose filters and baked for 2 h at 80°C in a vacuum 
oven.  Filter prehybridization and  hybridization reactions were those of 
Friedman et al. (17). Hybridizations were performed for 4 d at 42°C with 
,'J15  ×  106 cpm per reaction mixture in 200/zL vol. 
Protein Analysis 
Day 3 TA1 adipocytes (differentiated with 1.25  ×  10  -4 M  indomethacin) 
were incubated for 4 h in methionine-deficient  basal Eagle's medium with- 
out serum. 100 #Ci [35S]methionine (Bethesda Research Laboratories) was 
then added per milliliter tissue culture media for 1 h. Total cellular proteins 
were isolated and subjected to electrophoresis under denaturing conditions 
in  10%  polyacrylamide gels. 
Hybridization  Conditions 
Prehybridizations and hybridizations were performed at 42°C with 50% 
formamide, 5x  SSPE (Ix  SSPE  =  0.18  M NaC1,  10 mM sodium phos- 
phate, pH 7.7,  1 mM EDTA, 2×  Denhardt's reagent, (1×  =  0.02%  each 
of Ficoll, polyvinylpyrollidone, and BSA), 200 t~g/ml denatured Herring 
sperm DNA. Prehybridizations were from 2-25 h, hybridizations for 48 h. 
eDNA clones were nick translated (34)  or labeled by the random primer 
method (16),  and  1-5  ×  106 cpm of denatured 32P-labeled  eDNA was 
added for each milliliter of hybridization mix. Filters were washed in 2× 
SSPE, 0.1% SDS at room temperature, followed by two 30-min washes at 
50°C. When hybridization to more than one eDNA was carried out, filters 
were washed between hybridizations in boiling 0.1% SDS/0.1%  SSPE until 
no residual radioactivity remained.  Autoradiography was carried out at 
-70°C using XAR-5 film (Eastman Kodak Co., Rochester, NY) with one 
intensifying screen. Autoradiographs were analyzed using a scanning den- 
sitometer (Schleicher & Schuell, Inc., Keene, NH) attached to a reporting 
integrator (Hewlett-Packard Co., Palo Alto, CA). 
cDNA Clones 
cDNA clones of genes whose expression was enhanced in TA1 adipocytes, 
isolated from a library ofTA1 adipocytes by differential screening (10), were 
used to assess the effects of TNF and TGF-~ on adipocyte gene expression. 
In addition, a eDNA clone for glycerophosphate dehydrogenase (GPD) de- 
rived from 3"1"3 L1 cells was provided by Dr. Bruce Spiegelman./3-actin was 
obtained from Dr. Larry Kedes and pyruvate kinase from Dr. Keith Webster. 
Results 
Effect of  Recombinant TNF in Adipocytes and 
Preadipocytes 
As  seen  in Fig.  1,  5  d  of exposure  to  recombinant TNF 
reverts  lipid-laden  TA1  cells  to  preadipocyte  morphology 
with concomitant loss of lipid droplets. Preceding this rever- 
sal  in  differentiated  morphology  of  TA1  adipocytes  with 
Figure 1. TNF treatment reverts TA1  adipocytes to a preadipocyte morphology. TA1  adipocytes, a  stable murine adipogenic cell line (10), 
were stained for 10 rain with oil red O, which had been freshly prepared and filtered before use (32).  Top section shows TA1  adipocytes 
differentiated in the presence of 1.25  x  10  -4 M  indomethacin from day 0 to day 3.  Bottom section shows cells treated in exactly the same 
fashion as those in the top section, except that human recombinant TNF at 10 ng/ml was added to fully differentiated adipocytes for 5  d. 
Photographs are representative of an entire culture and have been duplicated in six independent experiments. 
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gene expression  in adipocytes.  Adipocytes (day 3) 
were incubated with (+) or without (-) TNF at 10 
ng/ml for 24 h. After cell lysis, RNA was isolated. 
10 #g RNA from each sample was fractionaWxl by 
electrophoresis on formaldehyde  gels and trans- 
ferred  to  nitrocellulose  filters.  Nick-translated 
cDNA clones of type I (47, GPD) and type II (20, 
27) adipose-inducible  genes (see text) were used to 
probe  these  filters  (43).  /3-actin  mRNA  is  un- 
changed under these experimental  conditions (data 
not shown). 
TNF, there is a rapid and coordinate decrease in the expres- 
sion of adipocyte-inducible genes, both those expressed only 
upon differentiation (class I: clones 47, GPD) and those ex- 
pressed before differentiation but augmented during differen- 
tiation (class II: clones 20, 27) (Fig. 2). Cell counts and mea- 
surements  of thymidine  incorporation  showed  that  these 
effects were obtained without any demonstrable proliferative 
effects on this cell line (data not shown). Thus TNF not only 
reversed the differentiated cellular phenotype, but caused a 
return to predifferentiated levels of gene expression of an en- 
tire set of genes specifically inducible  during adipogenesis 
in tissue culture. 
This effect of TNF on both class I and II adipocyte genes 
is seen in preadipocytes as well as adipocytes. Fig. 3 demon- 
strates that a gene actively transcribed before differentiation, 
but whose expression is further augmented during adipogen- 
esis (clone 27) maintains expression at predifferentiated lev- 
els with TNF treatment, just as class I genes (clones  1, 28, 
GPD) mRNAs are completely inhibited by TNE Thus, TNF 
inhibits expression of  both transcriptionally active and quies- 
cent genes in preadipocytes as well as repressing  their ex- 
pression in fully differentiated adipocytes. 
In most developmental systems, terminal differentiation is 
associated with coordinate transcriptional activation of genes 
for the major cellular products of the particular differentiated 
cell. We therefore tested whether the decreased mRNA levels 
we observed after TNF treatment of TA1 adipocytes is a re- 
sult of transcriptional inhibition of those genes. We had pre- 
Figure 3. TNF inhibits type I and type II adipose gene expression  in preadipocytes.  TA1 cells were grown in Eagle's basal medium sup- 
plemented  with 10% heat inactivated  FBS.  10  --6 M dexamethasone  and 1.25  x  10  -4 M indomethacin were present from day 0 to day 3. 
More than 90%  of the control cells  developed  a typical adipo~te morphology under these  conditions.  TNF at 10 ng/ml, was added to 
preadipocytes  2 d before they reached confluence and maintained  in the medium until harvest.  Total RNA was isolated and 10 ug of each 
sample used to prepare Northern blots.  Blots were probed with nick-translated  cDNAs corresponding to adipose-inducible  clones 1, 28, 
27, and GPD.  Lanes A contain RNA from control preadipocytes;  lanes B from control adipocytes harvested  at day 3; and lanes  C from 
TA1 cells treated  with TNF from day 2 to day 3. 
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level. 32P-labeled RNA  synthesized in isolated nuclei (see Mate- 
rials and Methods) was hybridized to 3/zg immobilized cDNA of 
clone  28  (28),  fl-actin  (A), or a  pEMBL plasmid  control  (E). 
Results are shown for nuclei obtained from cells before differentia- 
tion (PC), at day 3 when TNF was added 2 d before differentiation 
(TNF-PC), in adipocytes (CONTROL), and when TNF was added 
to already differentiated (day 3) adipocytes for 24 h (24). 
viously shown that  crude cachectin  preparations added  to 
preadipocytes prevented transcriptional activation of adipose 
genes (43), but were unable to show with these crude prepa- 
rations transcriptional inhibition of activated genes after the 
addition of TNF to already differentiated adipocytes. Yet any 
argument for a  major alteration of TNF-treated adipocytes 
towards a  less differentiated state requires a demonstration 
that the adipose genes return to a predifferentiated transcrip- 
tional  state.  To address this question,  we measured the in 
vitro elongation of mRNA initiated in vivo (nuclear "run-on" 
assay  [46])  to determine whether the  reduction  in  mRNA 
levels seen in Fig.  3 reflects decreased transcription of adi- 
pose genes. The results,  shown in Fig. 4,  demonstrate that 
the reduction in mRNA levels after addition of TNF to differ- 
entiated adipocytes correlates with the transcriptional inacti- 
vation of these adipose-inducible genes (data shown is for 
clone 28,  a type I gene). 
Effect of TGF-/3 on Adipocytes and Preadipocytes 
We next compared the effects of TNF on adipocyte gene ex- 
pression and on adipocyte morphology with another agent 
known to  inhibit adipocyte differentiation,  TGF-fl.  TGF-fl 
has been previously reported to inhibit differentiation when 
added to 3T3-L1 preadipocytes during the early stages of hor- 
monal exposure which triggers differentiation (20). Treatment 
during the latter stages of this period had no effect on either 
development of adipocyte morphology or appearance of GPDH 
activity.  In our  experiments,  we added  TGF-fl to  actively 
proliferating  TA1  preadipocytes  and  maintained  it  in  the 
medium continuously until control cells had achieved maxi- 
mal levels of adipocyte gene expression. In confirmation of 
previous experiments (20,  41),  we found that this treatment 
prevented the appearance of lipid droplets and expression of 
adipose genes (not shown).  We also added TGF-fl to fully 
differentiated  adipocytes and  measured its  effects on mor- 
phology and gene expression.  Unexpectedly, we found that 
TGF-fl could exert an effect on TA1  adipocytes as well as 
Figure 5. TGF-fl inhibits adipose 
gene expression in adipocytes with 
kinetics similar to TNE TA1 adi- 
pocytes were grown to confluence 
and differentiated  in indometha- 
cin for 3 d.  Media  was then re- 
placed with growth medium alone 
(Control); growth  medium plus 
0.5 ng/ml TGF-B, or growth me- 
dium plus 10 ng/ml TNE Dishes 
were harvested  after 4,  24,  and 
48 h.  RNA  was isolated and  10 
#g  RNA  from each  time point 
used to prepare  a northern  blot. 
The blot was hybridized with ra- 
diolabeled clone 28 cDNA. 
preadipocytes, resulting in the slow disappearance of lipid- 
laden cells from the population over the course of several 
days. We examined whether this morphological change was 
accompanied by changes in gene expression by treating adi- 
pocytes with  TGF-fl or TNF  and  analyzing expression of 
clone 28  after 4,  24,  and 48  h.  Fig.  5  demonstrates that 
TGF-fl reduces expression of this gene as rapidly and effec- 
tively as  TNF,  with  a  decrement in  expression evident as 
early as 4 h after treatment. Expression of the adipose gene 
clone 1 was also reduced by exposure to TGF-fl, although the 
control  gene pyruvate kinase was  unaffected (not  shown). 
These effects were achieved in the absence of any prolifera- 
tive response to TGF-fl (not shown). 
These experiments were performed with TGF-fl purified 
from porcine platelets, a preparation now known to contain 
multiple  forms  of TGF-fl,  including  TGF-fl~  and  TGF-fl2 
(12).  Although  TGF-fl~  and  TGF-fl2  have  generally  been 
found to exert similar effects, there are examples of biologi- 
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Figure 6.  Inhibition  of clone  28  gene expression  in adipocytes 
treated with TGF-/3~ or TGF-/32. Adipocytes were differentiated in 
the presence of indomethacin for 3 d and refed growth medium for 
24 h.  Fresh  medium containing either  no additions,  TGF-/3,, or 
TGF-/32 was then  added.  (a)  TGF-~ at indicated concentrations 
was added for 24 h. <3, TGF-/3~; e, TGF-~2. Cells were harvested, 
RNA isolated, and dot blots prepared. These were hybridized with 
clone 28 eDNA, washed, and then hybridized with pyruvate kinase 
(a gene whose expression is unaffected by TGF-/3). Autoradiograms 
were scanned with a densitometer. Units represent the ratio of sig- 
nal intensity obtained with clone 28 to that obtained with pyruvate 
kinase.  (b) Adipocytes were grown, exposed to 5 ng/ml TGF-/3,~ 
or 5 ng/ml TGF-/32 for various periods of time, and clone 28 ex- 
pression was analyzed as in a. 
cal  activities mediated by particular  forms of TGF-~ (29, 
36).  To determine  whether  effects on  gene  expression  in 
adipocytes could be mediated equally well by TGF-/3,  and 
TGF-/32,  we  measured  the  dose  response of clone  28  ex- 
pression  to  purified  preparations  of TGF-/3t  and  TGF-~2. 
Fig. 6 a demonstrates that the addition of either agent to fully 
differentiated adipocytes causes an equivalent reduction  in 
expression  of this  adipose  gene.  In  both  cases,  maximal 
effects are largely achieved by 24 h  (Fig.  6 b). 
In these experiments, adipocytes were grown and differen- 
tiated in standard medium containing FBS. In the experiment 
shown in Fig. 6, the addition of either TGF-/3~ or TGF-/32 at 
5 ng/ml reduces clone 28 expression  10-15-fold after 24 h 
treatment. However, the replacement of FBS with calf serum 
largely blocks this effect,  yielding only a  2.5-3.0-fold de- 
crease in clone 28 expression after comparable exposure to 
either  TGF-/3~ or TGF-/32 (Table I).  This  occurs  although 
(a) TGF-/3  blocks differentiation when added to preadipo- 
cytes in either serum (data not shown); and (b) differentiation 
Table I.  The Effect of TGF-~ on Clone 28 
Expression Is Serum Dependent 
Expression of clone 28 (in percent) 
Treatment  FBS  CS 
Control  100  104 
TGF-/3,  6  32 
TGF-B2  9  43 
TAI cells were grown and differentiated in the presence of indomethacin from 
day 0 to day 3 in media supplemented either with 10% FBS or 10% calf serum 
(CS). After withdrawal of indomethacin for 24 h, cells were refed medium con- 
mining either serum alone (Control);  5 ng/ml TGF-/3,,  or 5 ng/ml TGF-~:.  Af- 
ter an additional 24 h, cells were harvested. RNA was isolated and dot blots 
prepared. These were hybridized with radiolabeled clone 28 eDNA and pyru- 
vate kinase as described in the legend to Fig. 6. The ratio of signal intensities 
for these two probes in adipocytes differentiated in the presence of FBS was 
defined as  100%. 
proceeds to an equal extent in both sera as judged morpho- 
logically and by gene expression (Table I). These results sug- 
gest that modulation of adipose gene expression by TGF-/3 
may be more complex than that observed for TNE Our fur- 
ther  analysis  of the  ability  of these  agents  to  reverse the 
differentiated state therefore focused on TNE 
Hormonal Triggering of  Adipose Gene Expression in 
TNF-treated Adipocytes 
There are at least two ways to interpret the effects of TNF 
and TGF-/3 on mature adipocytes. These agents may selec- 
tively inhibit the expression of a  subset of genes,  some of 
which we have the ability to measure, without affecting the 
differentiated state per se. Alternatively, they may interfere 
with the regulatory processes that commit TA1 cells to differ- 
entiate  and  thereby cause them to return  to the prediffer- 
entiated state. We have taken advantage of the capability of 
glucocorticoid hormones such as dexamethasone (11) and the 
drug indomethacin (23) to precociously trigger the differen- 
tiation of TA1 preadipocytes in an effort to address this issue. 
Using dexamethasone and indomethacin,  induction of adi- 
pose-inducible mRNAs occurs earlier but, in general, not to 
a greater extent than in control cultures (11, 23). In addition, 
it appears that the effect is a triggering phenomenon,  since 
only transient exposure to the hormone or drug is required 
to accelerate differentiation.  We first reversed the differen- 
tiated  phenotype with  TNF  and  obtained  a  population  of 
cells, like those in Fig.  1, indistinguishable at a morphologic 
level from preadipocytes. We then asked whether the kinetics 
of reinduction of adipocyte-inducible mRNAs followed a pat- 
tern of drug-exposed or drug-naive cells. The results with in- 
domethacin  (Fig.  7) and dexamethasone (not shown) indi- 
cated  that  TA1  cells  which  were once  fully differentiated 
revert, upon TNF treatment, to a state indistinguishable from 
the preadipocyte, in that drug or hormonal treatment is again 
required  to  accelerate reexpression of adipocyte-inducible 
genes. 
Protein Synthetic Pattern in TNF-treated Adipocytes 
TNF causes differentiated adipocytes to acquire many of the 
features of gene  expression  and  hormonal  sensitivity that 
characterize the preadipocyte. To approach the question of 
whether TNF-treated adipocytes can be distinguished  from 
preadipocytes in another way, we sought to identify and char- 
acterize the TNF responsiveness of gene products that are 
specific to the preadipocyte. We therefore analyzed the newly 
synthesized proteins of preadipocytes, adipocytes, and adi- 
pocytes treated with TNF by labeling with [3sS]methionine. 
As seen in Fig. 8, at least two high molecular mass proteins 
that are actively synthesized in preadipocytes were not ob- 
served  in  differentiated adipocytes.  On treatment with  in- 
creasing  concentrations  of TNE  these  180-  and  220-kD 
proteins  reappear.  Moreover,  reexpression  of the  180-kD 
protein occurred within  several hours of exposure to TNF 
(not shown).  This experiment also demonstrates a number 
of other proteins whose synthesis is reduced but not abol- 
ished on differentiation; these also return to predifferentiated 
levels on TNF treatment.  The converse phenomenon  was 
also seen: in these gels, proteins can be identified whose ex- 
pression increased upon differentiation and returned to the 
predifferentiated level after TNF treatment. 
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tiation in TNF-treated adipocytes 
requires reexposure to indometh- 
acin.  Adipocytes  were  treated 
with TNF for 48 h at which time 
>90%  of  adipocyte-inducible 
RNA had disappeared.  TNF was 
removed (time 0) and cells refed 
with or without  1.25  x  10  -4 M 
indomethacin.  RNA  was  pre- 
pared from cells harvested at intervals from 12 h to 6 d. Northern blots were prepared using 10 #g RNA and probed with nick-translated 
clone 1. The kinetics of message accumulation for clone 1 in predifferentiated TA1 cells in both the presence and absence of indomethacin 
is virtually  identical to the kinetics (above) for TNF-treated  adipocytes (data not shown). 
Discussion 
From the RNA analyses and within the resolution of one- 
dimensional protein gels, it appears that the overall pattern 
of gene expression in TNF-treated adipocytes is  strikingly 
similar to that of the TA1 preadipocyte. Thus, by the criteria 
which have been traditionally used to define differentiation 
in these cultures,  the preadipocyte and TNF-treated adipo- 
cyte  cannot  be  distinguished.  Yet  are  these  cells  truly 
dedifferentiated? 
It appears that TNF is not simply acting as a lipolytic agent 
on these cells. For example, among the large number of new 
proteins  that  characterize  the  differentiated  adipocyte  are 
certain enzymes which have been used to define the differen- 
tiated phenotype. The appearance of these enzymes is inde- 
pendent of lipid accumulation in the adipocyte, since they are 
expressed in differentiated cells in which lipid accumulation 
is inhibited.  One such enzyme is GPD,  which is fully ex- 
pressed  in  adipocytes differentiated in biotin-deficient me- 
Figure 8. Protein synthetic pattern in TNF-treated adipocytes. The 
pattern of newly synthesized high molecular mass proteins in day 
3 adipocytes 24 h after the addition of 10 ng/ml TNF (TNF) is com- 
pared to proteins synthesized in preadipocytes (pre) and untreated 
adipocytes (fat). The arrows indicate bands present before differen- 
tiation that disappear or are greatly reduced on differentiation and 
return  with  TNF  treatment.  •  indicates  bands  present  in  the 
differentiated TA1 adipocyte which disappear with TNF treatment. 
Molecular masses of marker proteins that were subjected to coelec- 
trophoresis  are shown at right. 
dia,  conditions  that  completely  prevent  intracytoplasmic 
lipid accumulation (24). Such enzymes can serve as markers 
to distinguish between catabolic states where lipid accumula- 
tion might be suppressed from a predifferentiated precursor, 
the preadipocyte. As seen in Fig. 2, the mRNA for GPD was 
completely inhibited by TNF, strongly suggesting that TNF 
treatment does not simply prevent morphologic evidence of 
differentiation,  but  inhibits  those early  steps in gene tran- 
scription that characterize the differentiated state. 
However, although changes in gene expression engendered 
by TNF appear different from those seen in an adipocyte ex- 
posed to lipolytic stimuli, it is unlikely that the TNF-treated 
(or TGF-B-treated) adipocyte is identical in every respect to 
a preadipocyte. We have recently observed that the expres- 
sion of ferritin heavy chain is stimulated by TNF to levels 
exceeding those found in the preadipocyte (44);  thus there 
exists at least one gene that can distinguish control preadipo- 
cytes from TNF-treated adipocytes. In addition,  adipocytes 
acquire characteristics specific to the cytokine with which 
they were treated;  for example, TGF-~, like TNF,  inhibits 
differentiation when added to preadipocyte cultures (20) and 
causes decreases in lipid accumulation and reduction in ex- 
pression of adipose-inducible genes (Fig. 5), but does not in- 
duce expression of ferritin heavy chain (E Torti, unpublished 
observations). As more markers of TNF- and TGF-/3-treated 
cells are characterized, further distinctions among the pre- 
adipocyte,  TNF-,  and TGF-~-treated adipocyte will  likely 
become evident. 
The ability of TGF-B to reduce expression of adipose genes 
in  differentiated  adipocytes  has  not  been  previously  de- 
scribed. Ignotz and Massague (20) showed that 3T3L1  pre- 
adipocytes could be inhibited from differentiating into adipo- 
cytes by TGF-B. However, TGF-~ added during the last 16 h 
of hormonal induction failed to prevent differentiation. They 
therefore proposed that fully committed adipocytes become 
refractory to TGF-/3, although they do not lose TGF-B recep- 
tors. In our experiments, TA1 adipocytes exposed to TGF-/~ 
for prolonged periods of time (6 d)  gradually evidenced a 
loss of lipid.  The reduction in adipose gene expression was 
even more rapid, occurring in several hours in the presence 
of either  TGF-~  or  TGF-~2.  The  difference between  our 
results and those obtained in  3T3L1  cells (20)  may reflect 
differences in the cell lines used, or be related to the serum 
dependence of the TGF-/~ effect. 
We found the degree of decrease in gene expression medi- 
ated by TGF-B to be affected by serum components. This is 
perhaps not surprising in view of the highly interactive na- 
Torti et al. Modulation of Adipocyte Differentiation  1111 ture of TGF-~. For example, TGF-/3 synergizes with EGF in 
promoting anchorage-independent growth of NRK cells (1), 
and in the presence of PDGF, can stimulate colony formation 
in myc-transfected fibroblasts (35).  Maximal inhibition of 
adipose gene expression in adipocytes may therefore require 
the synergistic assistance of an additional serum factor(s), 
which may be variably represented in different sera. Alterna- 
tively, factor(s) present in some sera may inhibit the action 
of TGF-~ on fully differentiated adipocytes. Possible candi- 
dates include a TGF-/3 binding protein secreted by activated 
macrophages and capable of preventing binding of TGF-/3 to 
its receptor (2);  or growth factors, which have been shown 
to be capable of reversing some effects of TGF-O (e.g., its 
mitogenic action on osteoblasts, which can be reversed by 
EGF, PDGF, and TNF [9]). Although the response ofpreadi- 
pocytes to TGF-/3 appeared less dependent on serum factors 
than that of adipocytes, this may simply reflect an altered 
dose responsiveness to serum components in these two cell 
types. Alternatively, since TGF-/3 effects can be altered and 
even reversed depending on the state of differentiation of the 
target cell (37, 38), it is possible that TGF-/%dependent inhi- 
bition of differentiation is mechanistically independent from 
its ability to inhibit adipose gene expression in adipocytes. 
Clarification of these issues will require the use of defined 
growth factors in combination with TGF-~3; these experi- 
ments are currently in progress. Nevertheless, although the 
mechanism of action of TGF-~ on adipose genes may be 
more complex or more sensitive to environmental influences 
than that of TNF, it is clear that TGF-~, like TNF, can affect 
the expression of adipose genes in fully differentiated adipo- 
cytes. 
The ability of TNF and TGF-13 to alter the state of adipo- 
cyte differentiation and gene expression may have physiolog- 
ical relevance.  There is, for example, marked involution of 
adipocytes in mammary tissue during lactation (39), perhaps 
reflecting a reduced need for storing lipids and an increased 
requirement for lipid production in milk. The uncontrolled 
metabolic wasting associated with the cachexia of cancer or 
chronic infections is associated with a progressive loss of 
adipose tissue and a pattern of metabolic changes similar to 
those associated with cachectin/TNF production (5, 21, 22, 
30, 31). Whether TNF is a mediator of any of these processes 
in vivo is unknown. Nevertheless, the ability of TNF to con- 
vert mature adipocytes to ostensibly normal preadipocytes 
may be associated with physiological states in which both 
mobilization of energy stores and prevention of lipid storage 
are involved.  Interestingly, TGF-/3 has also been implicated 
in the response to stress and tissue damage (25, 42) and has 
recently been shown to inhibit mammary ductal growth in 
vivo (39).  Like TNF, the secretion of TGF-~ is accelerated 
in activated macrophages (2).  These observations, in con- 
junction with the similarity of effects of TNF and TGF-/3 on 
adipose cells which we report here,  make it tempting to 
speculate that these two disparate molecules, whose known 
functions show little overlap, may collaborate in the host re- 
sponse  to  tissue  injury  and  in  the  pathophysiology  of 
cachexia. 
Regardless of any hypothesis concerning the physiological 
role of TNF and TGF-/3 the effects on adipocytes we have de- 
scribed here are striking. By many criteria,  including the 
ability to rapidly and coordinately inhibit the expression of 
several  adipose-inducible  genes,  TNF  appears  to  revert 
differentiated TA1 cells to a state characteristic of preadipo- 
cytes.  TGF-~  also  is  capable  of affecting expression  of 
differentiated functions in adipocytes, although its mecha- 
nism of action may be more complex.  Elucidation of the 
mechanisms by which TNF and TGF-fl  exert their effects 
may provide insight into the events required for triggering the 
so-called "terminal" but largely reversible, differentiation of 
this cell line. 
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